Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

Not Recruiting

Trial ID: NCT04097145


To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Repair System in patients with symptomatic severe tricuspid regurgitation who have been determined to be at an intermediate or greater estimated risk of mortality with tricuspid valve surgery by the cardiac surgeon with concurrence by the local Heart Team

Official Title

A Prospective, Multicenter, Randomized, Controlled Pivotal Trial to Evaluate the Safety and Effectiveness of Transcatheter Tricuspid Valve Repair With the Edwards PASCAL Transcatheter Valve Repair System and Optimal Medical Therapy (OMT) Compared to OMT Alone in Patients With Tricuspid Regurgitation

Stanford Investigator(s)

Jack Boyd
Jack Boyd

Clinical Associate Professor, Cardiothoracic Surgery

Mirela Tuzovic

Clinical Assistant Professor, Medicine - Cardiovascular Medicine

Rahul P Sharma, MBBS, FRACP
Rahul P Sharma, MBBS, FRACP

Clinical Associate Professor, Medicine - Cardiovascular Medicine

Randall Vagelos, MD
Randall Vagelos, MD

Professor of Medicine (Cardiovascular)

David Lee, MD
David Lee, MD

Professor of Medicine (Cardiovascular Medicine)


Inclusion Criteria:

   - Eighteen (18) years of age or older

   - Despite medical therapy, per the local Heart Team, patient has signs of TR, symptoms
   from TR, or prior heart failure hospitalization from TR.

   - Severe or greater tricuspid regurgitation

   - New York Heart Association (NYHA) Class II-IVa or heart failure hospitalization in the
   prior 12 months

   - Patient is at an intermediate or greater estimated risk of mortality with tricuspid
   valve surgery as determined by the cardiac surgeon with concurrence by the local Heart

   - Patient is able and willing to give informed consent, follow protocol procedures, and
   comply with follow-up visit requirements

Exclusion Criteria:

   - Tricuspid valve anatomy not evaluable by TTE or TEE

   - Tricuspid valve anatomy precludes proper device deployment and function

   - Patient with refractory heart failure requiring, advanced intervention (i.e. patient
   has or will need left ventricular assist device, or transplantation) (ACC/AHA Stage D
   heart failure)

   - Presence of trans-tricuspid pacemaker or defibrillator leads which meet one of the

      1. Would prevent proper TR reduction due to interaction of the lead with the

      2. Were implanted in the RV within the last 90 days prior to the point of enrollment

   - Primary non-degenerative tricuspid disease

   - Previous tricuspid valve repair or replacement that would interfere with placement of

   - Clinically significant, untreated coronary artery disease requiring revascularization,
   unstable angina, evidence of acute coronary syndrome, recent myocardial infarction

   - Significant intra-cardiac mass, thrombus, or vegetation per echo core lab assessment

   - Deep vein thrombosis (DVT) or pulmonary embolism (PE) in the last 90 days

   - Recent Stroke

   - Active gastrointestinal (GI) bleeding

   - Presence of infiltrative cardiomyopathy or valvulopathy (including carcinoid,
   amyloidosis, sarcoidosis, hemochromatosis) or significant congenital heart disease,
   including but not limited to atrial septal defect, RV dysplasia, and arrhythmogenic RV

   - Need for emergent or urgent surgery for any reason, any planned cardiac surgery within
   the next 12 months (365 days), or any planned percutaneous cardiac procedure within
   the next 90 days

   - Any of the following cardiovascular procedures:

      1. Percutaneous coronary, intracardiac, or endovascular intervention within the last
      30 days prior to the point of enrollment

      2. Carotid surgery within 30 days prior to the point of enrollment

      3. Direct current cardioversion within the last 30 days prior to the point of

      4. Leadless RV pacemaker implant within the last 30 days prior to the point of

      5. Cardiac surgery within 90 days prior to the point of enrollment

   - Severe aortic, mitral and/or pulmonic valve stenosis and/or regurgitation

   - Known history of untreated severe symptomatic carotid stenosis or asymptomatic carotid

   - Active endocarditis within the last 90 days or infection requiring antibiotic therapy
   within the last 14 days

   - Patient is oxygen-dependent or requires continuous home oxygen

   - Pregnant, breastfeeding, or planning pregnancy within the next 12 months (365 days)

   - Concurrent medical condition with a life expectancy of less than 12 months in the
   judgment of the Investigator

   - Patient is currently participating in another investigational biologic, drug, or
   device clinical study

   - Patient has other medical, social, or psychological conditions that preclude
   appropriate consent and follow-up, or the patient is under guardianship

   - Any patient considered to be vulnerable


device: Edwards PASCAL System

drug: Optimal Medical Therapy

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305